In a startling revelation, Biotech Co. Zymergen Inc. announced its filing for Chapter 11 protection in Delaware this Tuesday. The numbers behind the story are staggering: assets and debts ranging from $100 million to a half-billion dollars. This comes as the firm expresses its intention to sell assets and resolve securities claims from a dramatic decline in share value after their 2021 public debut.

Biotech Co. Zymergen : Ginkgo Bioworks Enters the Scene

But here's the twist in our tale: Zymergen's current owner, Ginkgo Bioworks, has tossed its hat into the ring, hoping to snap up the assets. They've committed as the stalking horse bidder with a $5 million bid, willing to assume Zymergen's obligations. Eyes are now set on the December 13th auction where the future of Zymergen's assets will be determined.

The Rise and Fall of Hyaline

Drawing parallels to Icarus flying too close to the sun, Zymergen, just two years prior, had celebrated a massive $530 million windfall from its IPO. This capital injection was the catalyst behind the launch of Hyaline – a next-gen optical film series envisioned for state-of-the-art touch-screen gadgets. Yet, according to Claire Smith, Zymergen's SVP of Finance, subsequent data painted a different picture, casting shadows of doubt over the robust market potential of Hyaline. Technical glitches emerged when clients tried incorporating the product, leading Zymergen to realize that their initial demand forecasts might have been too rose-tinted.

The aftermath? A bombshell announcement: Zymergen no longer saw significant revenues on the horizon for 2021 or 2022. This revelation sent the company's stock into a freefall, plummeting by around 70%, and legal battles soon ensued as shareholders sought justice.

Ginkgo Bioworks Steps In, but Challenges Persist

2022 saw another plot twist as Ginkgo Bioworks acquired Zymergen, reshaping its business to focus primarily on services. Yet, even with a change in narrative, the ink on the balance sheet remained red. The subsequent months saw a massive downsizing, with 323 roles being axed.

Describing Chapter 11 as their beacon to enhance asset value via a court-overseen sales process and to stymie the cash hemorrhage, Smith revealed that the company has petitioned the Delaware court for initial motions, which includes permissions to persist in compensating employees and the appointment of a restructuring consultant.

As the story unfolds, a pivotal first-day hearing is slated for Wednesday at 12:30 p.m. EDT.

Efforts to solicit comments from Zymergen's representatives met with silence. The company's legal defense is currently spearheaded by Curtis S. Miller and Matthew O. Talmo of Morris Nichols Arsht & Tunnell LLP.